From: Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
Lowery et al. [14] (N = 158)
Churi et al. [37] (N = 55)
Ross et al. [38] (N = 28)
Zou et al. [39] (N = 102)
TP53 (34%), (%)
20
29
36
38
KRAS (25%), (%)
7
24
11
17
ARID1A (17%), (%)
23
